9 Meters Biopharma Q3 FY21: net loss $13.5M; diluted EPS −$1.00

Key figures from this report

These are the numbers 9 Meters Biopharma reported for Q3 FY21, the quarter ended Sep 30, 2021, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$13.5MAgainst −$8.3M in Q3 FY2010-Q income statement, on EDGAR
2. Diluted EPS−$1.00Against −$1.20 in Q3 FY20. Split-adjusted, as the tables show it; the filing reported −$0.0510-Q income statement, on EDGAR
3. Cash and cash equivalents$53.6M+331% from $12.4M in Q3 FY2010-Q balance sheet, on EDGAR
4. Cash from operations−$8.2MAgainst −$4.2M in Q3 FY2010-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters